Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.

BMC cancer·2023

Same author

Corrigendum to "SELNET clinical practice guidelines for soft tissue sarcoma and GIST" [Cancer Treat. Rev. 102 (2021) 102312].

Cancer treatment reviews·2023

Same author

Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10.

Critical reviews in oncology/hematology·2022

Same author

SELNET clinical practice guidelines for bone sarcoma.

Critical reviews in oncology/hematology·2022

Same author

SELNET clinical practice guidelines for soft tissue sarcoma and GIST.

Cancer treatment reviews·2021

Same author

Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas: An International Multicenter Study of 318 Cases.

The Journal of bone and joint surgery. American volume·2020

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Targeted therapies in bone sarcomas.

K Scotlandi¹, P Picci, H Kovar

¹Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy. katia.scotlandi@ior.it

Current Cancer Drug Targets

|December 23, 2009

Summary

New sarcoma therapies are crucial. This review explores novel targets like chimeric oncoproteins and IGF-IR, aiming for safer, more effective treatments with fewer side effects, especially for pediatric patients.

Area of Science:

Oncology
Cancer Therapeutics
Sarcoma Research

Background:

Sarcoma treatment needs innovation beyond dose-intensified chemotherapy due to severe toxicity and secondary malignancies.
Limited options exist for advanced or recurrent sarcoma, necessitating novel therapeutic strategies.
Pediatric sarcoma patients require treatments minimizing side effects, balancing efficacy with safety.

Purpose of the Study:

To review innovative therapeutic strategies for sarcoma treatment.
To highlight key targets for novel drug development in bone sarcomas.
To identify challenges for clinical translation of new targeted agents.

Main Methods:

Literature review of recent advancements in sarcoma therapy.
Focus on target identification in bone sarcomas.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Analysis of potential therapeutic targets including chimeric oncoproteins, IGF-IR, and tumor microenvironment.

Main Results:

Identified chimeric oncoproteins, insulin-like growth factor receptor (IGF-IR), and tumor/microenvironment interactions as promising targets.
Highlighted the need for dose intensification in localized sarcoma, despite toxicity concerns.
Emphasized the lack of effective treatments for progressive and metastatic disease.

Conclusions:

Novel targeted approaches combined with chemotherapy may reduce toxicity in pediatric sarcoma.
Further research is needed to address safety and efficacy concerns before clinical trials of new agents.
Developing effective drugs for advanced/metastatic sarcoma remains a critical unmet need.